Want to see SE:SEDANA full AI Analyst Report?
SEDANA Stock Chart & Stats
kr12.70
kr0.21(2.42%)
At close: 4:00 PM EDT
kr12.70
kr0.21(2.42%)
Day’s Range― - ―
52-Week Rangekr7.90 - kr14.42
Previous CloseN/A
Volume23.72K
Average Volume (3M)239.95K
Market Cap
kr1.10B
Enterprise Valuekr778.04
Total Cash (Recent Filing)kr51.79M
Total Debt (Recent Filing)kr7.32M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Oct 22, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding99,336,960
10 Day Avg. Volume328,190
30 Day Avg. Volume239,954
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)kr208.96M
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low leverage and substantial equity relative to assets provide a meaningful solvency cushion. This reduces interest and refinancing pressure, preserving financial flexibility while Sedana develops adoption of its ICU sedation platform.
Strong Gross MarginA strong gross margin indicates that Sedana’s products retain meaningful economic value after direct production costs. If commercial adoption improves, this margin profile could support operating leverage and a path toward more sustainable profitability.
Narrowing LossesThe historical reduction in loss severity suggests some progress in cost control or operating efficiency. Although the company remains loss-making, continued improvement could reduce the earnings burden as its inhaled ICU sedation business develops.
Bears Say
Revenue ContractionA material reversal in revenue growth weakens evidence of sustained customer adoption and market expansion. Unless sales recover, the contraction can limit operating leverage, prolong losses, and reduce the resources available for commercial development.
Persistent Cash BurnConsistently negative operating and free cash flow shows that the core business is not yet self-funding. Sustained cash consumption increases reliance on existing liquidity or external financing and can constrain investment in sales, clinical work, and expansion.
Ongoing UnprofitabilityPersistent operating and net losses, combined with negative returns on equity, indicate that capital is not yet generating adequate shareholder returns. This weak profitability may remain a structural constraint until revenue scale and cost absorption improve.
Sedana Medical AB News
SEDANA FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was kr7.90 and its highest was kr14.42 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is kr1.10B.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Oct 22, 2026 which is in 49 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Jul 17, 2026. The company reported -kr0.1 earnings per share for the quarter, missing the consensus estimate of -kr0.085 by -kr0.015.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is -0.09.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -kr0.1 in its last earnings report, missing expectations of -kr0.085. Following the earnings report the stock price went down -3.786%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in SE:SEDANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ) is a medical technology firm that engineers, promotes, and distributes healthcare devices both within Sweden and across global markets. Its product portfolio includes the Sedaconda ACD-L and Sedaconda ACD, single-use medical tools designed for delivering volatile anesthetics, alongside the Sedaconda Syringe (a 50/60ml syringe) and a Sedaconda ACD starter kit. The company also provides FlurAbsorb and FlurAbsorb-S, active carbon filtration systems engineered to collect residual anesthetic gases discharged by ventilators. Complementing these are the FlurAbsorb accessory kit, which facilitates connecting ventilator exhausts and gas monitors to the filters, and the FlurAbsorb mount, used to secure the filter during anesthetic gas removal. Further offerings encompass the AMG-06 Gas Monitor, which enables ongoing, non-invasive sidestream measurement of carbon dioxide and anesthetic levels in inhaled and exhaled breaths. Additionally, they supply the Sedaconda Filling Adapter, a disposable tool for securely and simply transferring isoflurane from its container to a Sedaconda Syringe, as well as an array of supplemental items like DRYLINE II Water Traps, the WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Lines. Established in 1999, Sedana Medical AB (publ) maintains its corporate headquarters in Danderyd, Sweden.